Full Press Release Details
National Stock Exchange of India Ltd. (Scrip Code:
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
This is in reference to Regulation 30(11) of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") regarding a news article
reported in electronic media https://economictimes.indiatimes.com on June 7, 2024, with the heading "Mankind Pharma in race with
PEs buy BSV Group at possible valuation of Rs 13,000 crore".
The said news article,
inter alia, talks about "Dr Reddy's Laboratories may also join the fray, having sought extra time to submit a bid for
the Advent International portfolio company and that its non-binding bid is expected to be filed this week". In this regard, please
note that the Company evaluates various strategic opportunities in the ordinary course for growth and expansion of its business.
At this stage, there is no material event/ information that requires disclosure under Regulation 30 of the SEBI Listing Regulations. The
Company will make appropriate disclosures in compliance with applicable laws, as and when required.
Further, in compliance with Regulation 30 of the SEBI
Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such
disclosure under the said Regulations.
This is for your information.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer and